Clinical Trial Update: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of recombinant vaccinia virus JX-594 for refractory solid tumors completed, evaluating melanoma, lung cancer, renal cell carcinoma, and squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Melanoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• JX-594 (Pexa-Vec)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Melanoma, Lung Cancer | Phase 1 | Status: COMPLETED